Drug Development Strategy
End-to-end clinical R&D planning from target validation through regulatory submission, with indication-specific protocol design grounded in the mechanism of action and patient population.
Key Capabilities
- Clinical Development Strategy & IND-enabling study design
- Phase I–III clinical protocol development
- Endpoint selection and biomarker strategy
- Statistical analysis plan consultation
- NDA/BLA submission planning and execution
